653 related articles for article (PubMed ID: 16472560)
1. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
2. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S; Kaye JA; Li L; Jick H
Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
Cole JA; Norman H; Doherty M; Walker AM
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
[TBL] [Abstract][Full Text] [Related]
5. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
Jick SS; Jick H
Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
[TBL] [Abstract][Full Text] [Related]
6. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Brenner P
Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
[No Abstract] [Full Text] [Related]
7. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.
Dore DD; Norman H; Loughlin J; Seeger JD
Contraception; 2010 May; 81(5):408-13. PubMed ID: 20399947
[TBL] [Abstract][Full Text] [Related]
8. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
[TBL] [Abstract][Full Text] [Related]
9. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction.
Jick SS; Jick H
Pharmacotherapy; 2007 Feb; 27(2):218-20. PubMed ID: 17253912
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
11. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
14. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
15. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
16. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
17. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
Sidney S; Petitti DB; Soff GA; Cundiff DL; Tolan KK; Quesenberry CP
Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
[TBL] [Abstract][Full Text] [Related]
20. A clinical study of transdermal contraceptive patch in Thai adolescence women.
Piyasirisilp R; Taneepanichskul S
J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
